Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

2.6K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.6K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

880
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
880
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel P2X4 Receptor Antagonist MRS4719 Improves Ischemia/reperfusion Injury in Mice.

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents·2026
Same author

MRS2339, a cardiac P2X4 receptor nucleotide activator, improves systolic function in heart failure.

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents·2026
Same author

Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Ontology accelerates few-shot learning capability of large language model: A study in extraction of drug efficacy in a rare pediatric epilepsy.

International journal of medical informatics·2025
Same author

Adenosine A<sub>1</sub> and A<sub>3</sub> Receptors: Distinct Cardioprotection.

Drug development research·2025
Same author

Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases.

Scientific reports·2024

Related Experiment Video

Updated: Jul 5, 2025

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

21.7K

Adenosine Receptor Subtypes and Cardioprotection.

Jang Eun Lee1, Karen Wilcox2, Kenneth A Jacobson3

  • 1Department of Medicine, Cardiovascular Division, Philadelphia, Pennsylvania.

Drug Development Research
|January 18, 2024
PubMed
Summary

Brief ischemia protects heart cells by activating adenosine receptors (A1 and A3) and KATP channels. This preconditioning phenomenon reduces injury during sustained ischemia, preserving ATP and cell viability.

Keywords:
adenosineischemiamyocardiumpurinergicreceptor

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.4K

Related Experiment Videos

Last Updated: Jul 5, 2025

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

21.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.4K

Area of Science:

  • Cardiology
  • Cellular Physiology
  • Molecular Biology

Background:

  • Myocardial infarction size is reduced by brief ischemic periods, a process termed preconditioning.
  • Adenosine receptor subtypes and their signaling pathways are implicated in cardiac preconditioning.

Purpose of the Study:

  • To investigate the role of adenosine receptor subtypes in cardiac preconditioning using a ventricular myocyte model.
  • To elucidate the signaling mechanisms linking adenosine receptors to the protective effects of preconditioning ischemia.

Main Methods:

  • A cardiac ventricular myocyte model was used to simulate preconditioning ischemia (5 min) followed by sustained ischemia (90 min).
  • Adenosine receptor agonists (CCPA, IB-MECA) and antagonists (DPCPX, MRS1191, 8-SPT) were employed to assess receptor involvement.
  • KATP channel activity was modulated using pinacidil (opener) and glibenclamide (antagonist).
  • Cellular ATP content, cell viability (percentage killed), and creatine kinase release were measured.

Main Results:

  • Preconditioning ischemia protected myocytes against injury, preserving ATP and reducing cell death and creatine kinase release.
  • Activation of adenosine A1 and A3 receptors mimicked the protective effects of preconditioning ischemia.
  • Blockade of A1 and A3 receptors during preconditioning ischemia attenuated or abolished the protective effect.
  • KATP channel activation was necessary for preconditioning, as glibenclamide blocked the protective effect.
  • A signaling pathway involving phospholipase C/D, protein kinase C, and KATP channels was proposed.

Conclusions:

  • Adenosine A1 and A3 receptors play a crucial role in mediating the cardioprotective effects of ischemic preconditioning.
  • KATP channels are essential effectors in the preconditioning signaling pathway.
  • A detailed model for the triggering and mediation of ischemic preconditioning is proposed, involving receptor-mediated activation of intracellular signaling cascades.